Author

Bo Wei

Institution: BeOne Medicines (Switzerland)

Observed institution: BeOne Medicines (Switzerland)

OpenAlex ID: A5122763264

Tislelizumab (TIS) + chemotherapy (CT) vs placebo (PBO) + CT as first-line treatment for locally advanced (LA), unresectable esophageal squamous cell carcinoma (ESCC): PD-L1 tumor area positivity (TAP) score ≥1% subgroup analysis of RATIONALE-306.

2026 · Harry H. Yoon, Sunnie S. Kim, et al. · Journal of Clinical Oncology

Works count: 1

Citation count:

H-index:

I10-index: